Evidence map›Paper›PMID 31906163›Full record

ReviewJournal of clinical medicine2019

Point-Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A Status Update.

Michelle A Bulterys, Bradley Wagner, Maël Redard-Jacot, Anita Suresh, Nira R Pollock, Emmanuel Moreau, Claudia M Denkinger, Paul K Drain, Tobias Broger

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 8 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 8 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Ultrasensitive Enzyme-Free Detection of Proteins on Magnetic Beads.Journal of the American Chemical Society · 2026
    Article
  18. Article
  19. Review
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Michelle A BulterysFIND, 1202 Geneva, Switzerland.
Bradley WagnerInstitute of Disease Modeling, Bellevue, WA 98005, USA.
Maël Redard-JacotFIND, 1202 Geneva, Switzerland.
Anita SureshFIND, 1202 Geneva, Switzerland.
Nira R PollockDepartment of Laboratory Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
Emmanuel MoreauFIND, 1202 Geneva, Switzerland.
Claudia M DenkingerFIND, 1202 Geneva, Switzerland.
Paul K DrainInternational Clinical Research Center, University of Washington, Seattle, WA 98105, USA.
Tobias BrogerFIND, 1202 Geneva, Switzerland.
FIND · CHBellevue Hospital Center · USBoston Children's Hospital · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most diagnostic tests for tuberculosis (TB) rely on sputum samples, which are difficult to obtain and have low sensitivity in immunocompromised patients, patients with disseminated TB, and children, delaying treatment initiation. The World Health Organization (WHO) calls for the development of a rapid, biomarker-based, non-sputum test capable of detecting all forms of TB at the point-of-care to enable immediate treatment initiation. Lipoarabinomannan (LAM) is the only WHO-endorsed TB biomarker that can be detected in urine, an easily collected sample. This status update discusses the characteristics of LAM as a biomarker, describes the performance of first-generation urine LAM tests and reasons for slow uptake, and presents considerations for developing the next generation of more sensitive and impactful tests. Next-generation urine LAM tests have the potential to reach adult and pediatric patients regardless of HIV status or site of infection and facilitate global TB control. Implementation and scale-up of existing LAM tests and development of next-generation assays should be prioritized.

Indexed as

Lipoarabinomannan (LAM), urinary testsTuberculosis (TB), diagnostics

Identifiers

PMID31906163
PMCPMC7020089
OpenAlexW2998321752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.